

BIODELIVERY SCIENCES INTERNATIONAL INC

Form 10-Q/A

March 30, 2018

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

(Amendment No. 1)

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934**

For the quarterly period ended September 30, 2017

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934**

For the transition period from _____ to _____

Commission file number 001-31361

BioDelivery Sciences International, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization) 4131 ParkLake Ave., Suite 225, Raleigh, NC (Address of principal executive offices) Registrant's telephone number (including area code): 919-582-9050	35-2089858 (I.R.S. Employer Identification No.) 27612 (Zip Code)
--	---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of large accelerated filer, accelerated filer and smaller reporting company, or emerging growth company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	Accelerated filer
Non-accelerated filer (Do not check if a smaller reporting company)	Smaller reporting company
	Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of November 9, 2017, there were 55,898,927 shares of company Common Stock issued and 55,883,436 shares of company Common Stock outstanding.

EXPLANATORY NOTE

This Amendment No. 1 to Form 10-Q (this Form 10-Q/A) amends the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2017 (the Form 10-Q) originally filed by BioDelivery Sciences International, Inc. (the Company) with the Securities and Exchange Commission on November 9, 2017.

The sole purpose of this Form 10-Q/A is to file as a replacement exhibit to the Form 10-Q an updated redacted version of the License Agreement dated July 12, 2017 (the License Agreement) by and among the Company and the Company's wholly-owned subsidiary, on the one hand, and Purdue Pharma, on the other hand. The remainder of the Form 10-Q remains unchanged.

Item 6. Exhibits.

Exhibit

No.

Description

10.1	<u>License Agreement dated July 12, 2017 by and between the Company, Arius and Purdue Pharma (+)</u>
------	--

* Confidential treatment is requested for certain portions of this exhibit pursuant to 17 C.F.R. Sections 200.8(b)(4) and 240.24b-2.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BIODELIVERY SCIENCES INTERNATIONAL, INC.

Dated: March 30, 2018

By: /s/ Ernest R. De Paolantonio
Name: Ernest R. De Paolantonio
Title: Chief Financial Officer, Treasurer and
Secretary